ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Genetic Biomarkers"

  • Abstract Number: 2827 • 2017 ACR/ARHP Annual Meeting

    A Novel Statistical Method to Resolve Cellular Heterogeneity in Disease Tissues: Integrating Transcriptomic Data in Accelerating Medicines Partnership (AMP) – RA Network Phase 1 Data

    Fan Zhang1, Kamil Slowikowski2, Chamith Fonseka1, Kevin Wei3, Maria Gutierrez-Arcelus4, James Lederer5, Nir Hacohen6, Vivian P. Bykerk7, Michael Holers8, Peter Gregersen9, Mandy J. McGeachy10, Larry W. Moreland11, Andrew Filer12, Costantino Pitzalis13, Yvonne C. Lee14, Jennifer H. Anolik15, Michael Brenner4 and Soumya Raychaudhuri16, 1Divisions of Genetics and Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 2Division of Medicine and Rheumatology, Brigham and Women's Hospital, Harvard Medical Schoo, Boston, MA, 3Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 4Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 5Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 6Harvard Medical School, Boston, MA, 72-005, Mt Sinai Hospital, Toronto, ON, Canada, 8Medicine, Division of Rheumatology, University of Colorado Denver, Aurora, CO, 9The Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY, 10Medicine, University of Pittsburgh, Pittsburgh, PA, 11Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 12Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham, United Kingdom, 13Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, 14Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 15Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, 16Division of Medicine and Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Detecting distinct cellular subsets in disease tissues is key to understanding the pathogenesis of immune diseases, for example in synovial tissues in rheumatoid arthritis…
  • Abstract Number: 2828 • 2017 ACR/ARHP Annual Meeting

    A Graph-Theoretic-Approach Applied to Modular-Repertoire-Analysis Identifies Shared Gradual Whole Blood Interferon Signatures in Systemic Lupus Erythematosus and Primary Sjögren’s Syndrome Patients and Reveals New Interferon-Related Modules in Disease Progression

    Ilya Korsunski1, Noémie Jourde-Chiche2, Peter Gregersen3, Damien Chaussabel4, Laurent Chiche5 and Naomi I. Maria6, 1Center for Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, 2Nephrology, AP-HM, Department of Nephrology, CHU Conception, Marseille, France, 3Robert S. Boas Center for Genomics and Human Genetics, Feinstein Institute for Med Res, Manhasset, NY, 4Translational Medicine, Sidra Medical and Research Center, Doha, Qatar, 5Internal medicine, Hopital europeen, Marseille, France, 6Center for Autoimmune and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY

    Background/Purpose: There is significant clinical and molecular heterogeneity among patients suffering from systemic autoimmune diseases, such as systemic lupus erythematosus (SLE) and primary Sjögren’s Syndrome…
  • Abstract Number: 2905 • 2017 ACR/ARHP Annual Meeting

    TET2 Mutation Is Significantly Associated with the Development of Autoimmune Disorder in Patients with Myelodysplastic Syndrome

    Yoon-Jeong Oh1, Dong-Yeop Shin2, Sang Mee Hwang3, Eun Young Lee4, Yeong Wook Song5, Dong-Soon Lee3 and Jin Kyun Park6, 1Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), 2Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), 3Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), 4Seoul National University College of Medicine, Seoul, Korea, Republic of (South), 5Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Koer, Seoul, Korea, Republic of (South), 6Division of Rheumatology, Seoul National University Hospital, Seoul, Korea, Republic of (South)

    Background/Purpose: Myelodysplastic syndrome (MDS) is characterized by ineffective hematopoiesis in bone marrow and peripheral cytopenia. Various genetic mutations contribute to MDS. Common mutations affect genes…
  • Abstract Number: 178 • 2017 ACR/ARHP Annual Meeting

    Genome-Wide DNA Methylation Study in Lupus in an Admixed Mexican Population

    Maria Teruel1, Patrick Coit2, Mikhail Dozmorov3, Mario Cardiel4, Ignacio Garcia-De La Torre5, Marco A Maradiaga-Ceceña Sr.6, José Francisco Moctezuma7, Maria Teresa Tusié-Luna8, Marta Alarcón-Riquelme9,10 and Amr H Sawalha2, 1GENYO, Center for Genomics and Oncological Research Pfizer/University of Granada/Andalusian Regional Government, Granada, Spain, 2Division of Rheumatology, University of Michigan, Ann Arbor, MI, 3Department of Biostatistics, Virginia Commonwealth University, Richmond, VA, 4Centro de Investigación Clínica de Morelia SC, Morelia, Mexico, 5Immunology & Rheumatology, Centro de Est. de Invest. Bas. y Clin., S.C., Guadalajara, JAL, Mexico, 6Hospital General de Culiacán, Culiacán, Mexico, 7Servicio de Reumatología, Hospital General de Mexico, Ciudad de Mexico, Mexico, 8Medicina Genómica y Toxicología Ambiental, Universidad Nacional Autonoma de Mexico, Ciudad de Mexico, Mexico, 9Uppsala University, Uppsala, Sweden, 10Centro de Genomica e Investigación Oncológica, Pfizer-University of Granada-Junta de Andalucía, Granada, Spain

    Background/Purpose: Our knowledge about the pivotal role DNA methylation plays in the pathogenesis of SLE has significantly increased in the last few years. However, we…
  • Abstract Number: 1016 • 2017 ACR/ARHP Annual Meeting

    The Genetic Biomarkers to Predicting Response of TNF Inhibitors Treatment in Rheumatoid Arthritis

    So-Young Bang1, Youngho Park2, Kwangwoo Kim3, Young Bin Joo4, Soo-Kyung Cho5, Chan-Bum Choi1, Yoon-Kyoung Sung2, Tae-Hwan Kim2, Jae-Bum Jun1, Dae-Hyun Yoo1, Hye-Soon Lee6 and Sang-Cheol Bae7, 1Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), 2Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), 34Department of Biology, Kyung Hee University, Seoul, Korea, Republic of (South), 4Internal Medicine, Department of Rheumatology, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Gyeonggido, Korea, Republic of (South), 5Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), 6Hanyang University Guri Hospital, Gyeonggi-do, Korea, Republic of (South), 7Department of Rhematology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South)

    Background/Purpose: Although pharmacogenetic studies of TNF inhibitors (TNFi) response presented the estimates of high heritability, only few loci with suggestive weak association as biomarkers for…
  • Abstract Number: 1028 • 2017 ACR/ARHP Annual Meeting

    Association of a Non-Synonymous, Loss-of-Function, Variant in NOD2 with Reduced Tissue Damage in ACPA +Ve RA

    Ricardo Segurado1, Denis Shields1, Rachel Knevel2, Annette H.M. van der Helm-van Mil3, Tom W.J. Huizinga4 and Anthony G. Wilson5, 1University College Dublin, Dublin, Ireland, 2Medical and Population Genetics Program, Broad Institute of MIT and Harvard, Cambridge, MA, 3Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, 5UCD School of Medicine and Medical Science, Conway Institute, University College Dublin, Dublin, Ireland

    Background/Purpose: The functional capacity of individuals with rheumatoid arthritis (RA) is related to the severity of damage to bone and cartilage within joints. This is…
  • Abstract Number: 34 • 2017 Pediatric Rheumatology Symposium

    The SLCO1B1 *14 Allele is Associated with Poor Response to Subcutaneous Methotrexate in Patients with Juvenile Idiopathic Arthritis

    Halima Moncrieffe1, Laura B Ramsey2, Marc Sudman3, Beth Gottlieb4, Carl D Langefeld5, Daniel Lovell6, Susan D Thompson7 and JIA Gene Expression Study Consortium, 1Center for Autoimmune Genomics and Etiology and Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Division of Research in Patient Services, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, 5Department of Biostatistical Sciences and Center for Public Health Genomics, Wake Forest School of Medicine, Winston-Salem, NC, 6Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 7Center for Autoimmune Disease Genomics and Etiology and Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose: Variants in the SLCO1B1 gene, encoding a hepatic methotrexate (MTX) transporter, affect clearance of high-dose MTX in leukemia patients.  We aimed to assess the…
  • Abstract Number: 58 • 2016 ACR/ARHP Annual Meeting

    Detecting Novel Candidate Risk Genes in Rheumatoid Arthritis with Gene-Based Association Testing

    Aleksander Lenert1 and David Fardo2, 1Internal Medicine, Div. of Rheumatology, University of Kentucky, Lexington, KY, 2Biostatistics, College of Public Health, University of Kentucky, Lexington, KY

    Background/Purpose: Rheumatoid arthritis (RA) is driven by immune-system dysfunction with contribution from genetic risk factors. Emerging data from genomewide association studies (GWAS) of single nucleotide…
  • Abstract Number: 60 • 2016 ACR/ARHP Annual Meeting

    A Single Nucleotide Polymorphism of IL6-Receptor Is Associated with Response to Tocilizumab in Rheumatoid Arthritis: Results from Toci and ROC Studies

    Cécile Luxembourger1, Adeline Ruyssen-Witrand2, Yannick Degboé3, Alain G. Cantagrel1, Arnaud CONSTANTIN4, Philippe Gaudin5, Christian Jorgensen6, Jean-Francis Maillefert7, Hubert Marotte Sr.8, Delphine Nigon9, Daniel Wendling10, Jacques-Eric Gottenberg11 and Yves-marie Pers12, 1Rheumatology, Centre Hospitalier Universitaire, Toulouse Purpan, Toulouse, France, 2Rheumatology Center, Purpan University Hospital, Toulouse, France, 3Rheumatology, Rheumatology Center, Purpan University Hospital, Toulouse, France, 4Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, 5Rheumatology, Grenoble University Hospital, France, Grenoble, France, 6Inserm u844, Unite ImmunoRhumatologie Therapeutique, Montpellier, France, 7Rheumatology, University Hospital, Dijon, France, 8CHU de St Etienne, Service de rhumatologie, St Etienne, France, 9CHU Purpan, Toulouse, France, 10Rheumatology, Besançon university hospital, Besançon, France, 11Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 12coordination RIC SUD, Montpellier, France

    Background/Purpose: Biological agents (boDMARDs) have modified the therapeutic management of patients with rheumatoid arthritis (RA). However, boDMARDs can induce sustained remission in only 30% of…
  • Abstract Number: 67 • 2016 ACR/ARHP Annual Meeting

    Polymorphisms of ERAP1, IL23R and TRAILR1 Are Associated with MRI-Sacroiliitis in Early Axial Spondyloarthritis: Data from the French DESIR Cohort

    Cécile Luxembourger1, Yannick Degboé2, Alain Cantagrel3, Delphine Nigon4, Pascal Claudepierre5, Arnaud CONSTANTIN6 and Adeline Ruyssen-Witrand7, 1Rheumatology, Centre Hospitalier Universitaire, Toulouse Purpan, Toulouse, France, 2Rheumatology, Rheumatology Center, Purpan University Hospital, Toulouse, France, 3Rheumatology, INSERM CNRS UMR 1043, Paul Sabatier University Toulouse, Purpan Teaching Hospital, Toulouse, France, 4CHU Purpan, Toulouse, France, 5Hôpital Henri Mondor, Créteil, France, 6Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, 7Rheumatology Center, Purpan University Hospital, Toulouse, France

    Polymorphisms of ERAP1, IL23R and TRAILR1 are associated With MRI-Sacroiliitis in Early Axial Spondyloarthritis: Data from the French DESIR Cohort Background/Purpose: Spondyloarthritis (SpA) is a…
  • Abstract Number: 804 • 2016 ACR/ARHP Annual Meeting

    Combined-Phenotype Meta-GWAS in Systemic Sclerosis and Rheumatoid Arthritis Identifies IRF4 As a New Common Susceptibility Locus

    Elena Lopez-Isac1, Shervin Assassi2, Carmen Pilar Simeón3, Patricia Carreira4, Norberto Ortego Centeno5, Benjamin Fernandez Gutierrez6, Alejandro Balsa7, Miguel Angel González-Gay8, Lorenzo Beretta9, Claudio Lunardi10, Gianluca Moroncini11, Torsten Witte12, Nicolas Hunzelmann13, Joerg HW Distler14, Gabriela Riekemasten15, Annette HM van der Helm-van Mil16, Jeska K. de Vries-Bouwstra17, Cesar Magro-Checa18, Alexandre E. Voskuyl19, Madelon C. Vonk20, Øyvind Molberg21, Tony Merriman22, Roger Hesselstrand23, Annika Nordin24, Leonid Padyukov25, Ariane L. Herrick26, Stephen Eyre27, Christopher Denton28, Carmen Fonseca29, Timothy R.D.J. Radstake30, Jane Worthington31, Maureen D Mayes2 and Javier Martín1, 1Institute of Parasitology and Biomedicine López-Neyra, IPBLN-CSIC, Granada, Spain, 2Department of Internal Medicine - Rheumatology, University of Texas-McGovern Medical School, Houston, TX, 3Internal Medicine, Hospital Universitari Vall d'Hebron, Barcelona, Spain, 4Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, 5Medicine Department, Hospital Universitario San Cecilio, Granada, Spain, 6Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, 7Department of Rheumatology, Hospital La Paz, Madrid, Spain, 8School of Medicine, University of Cantabria, Santander, Spain, 9Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, 10Department of Medicine, Università degli Studi di Verona, Verona, Italy, 11Dipartimento di Scienze mediche e Chirurgiche, Università politecnica delle Marche and Ospedali Riuniti, Ancona, Italy, 12Department of Clinical Immunology and Rheumatology, Hannover Medical School, Hannover, Germany, 13Department of Dermatology, University of Cologne, Cologne, Germany, 14Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, 15Department of Rheumatology, University of Lübeck, Luebeck, Germany, 16Rheumatology, Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 17Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 18Department of Rheumatology, Leiden University Medical Center, Leiden, Spain, 19Rheumatology, Amsterdam Rheumatology and immunology Center, Location VU University Medical Center, Amsterdam, Netherlands, 20Department of the Rheumatic Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 21Rheumatology, Oslo University Hospital, Oslo, Norway, 22Department of Biochemistry, University of Otago, Otago, New Zealand, 23Department of Rheumatology, Lund University, Lund, Sweden, 24Department of Rheumatology, Karolinska Institute, Stockholm, Sweden, 25Unit of Rheumatology, Department of Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, 26Centre for Musculoskeletal Research, University of Manchester, MAHSC, Salford Royal Hospital, Manchester, United Kingdom, 27The University of Manchester, Manchester, United Kingdom, 28Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, 29Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom, 30Laboratory of Translational Immunology, UMC Utrecht, Utrecht, Netherlands, 31Arthritis Research UK Epidemiology Unit, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom

    Background/Purpose: Genome-wide association studies (GWASs) have revolutionized our understanding of the genetic component of complex autoimmune diseases (ADs) by the identification of thousands of susceptibility…
  • Abstract Number: 1821 • 2016 ACR/ARHP Annual Meeting

    Demethylated CD4+CD28+KIR+CD11ahi T Cells Are Characterized By a Pro-Inflammatory Transcriptome and Interact with Genetic Risk to Predict Disease Activity in Lupus

    Paul Renauer1, Patrick Coit1, Faith Strickland2, Elizabeth Gensterblum1, Mikhail Ognenovski1, Bruce Richardson3 and Amr Sawalha4, 1Division of Rheumatology, University of Michigan, Ann Arbor, MI, 2Rheumatology, University of Michigan, Ann Arbor, MI, 3Rheumatology, University of Michigan and the Ann Arbor VA, Ann Arbor, MI, 4Internal Medicine-Rheumatology, University of Michigan, Ann Arbor, MI

    Background/Purpose:  T cell DNA methylation defects play an important role in the pathogenesis of systemic lupus erythematosus. A CD4+CD28+ T cell subset characterized by overexpression…
  • Abstract Number: 1841 • 2016 ACR/ARHP Annual Meeting

    Dysregulation of the Splicing Machinery Components in Leukocytes from Patients with Systemic Lupus Erythematosus: Influence on Autoimmune and Atherothrombotic Mechanisms

    Chary Lopez-Pedrera1, Sergio Pedraza-Arévalo2, Mercedes del Río-Moreno2, Maria Ángeles Aguirre Zamorano1, Patricia Ruiz-Limon3, Nuria Barbarroja1, Yolanda Jiménez-Gómez1, Ivan Arias de la Rosa3, Eduardo Collantes-Estévez1, Pedro Segui1, Maria Jose Cuadrado4, Justo P Castaño2, Raul M Luque2 and Carlos Perez-Sanchez1, 1Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 2Department of Cell Biology, Physiology and Immunology. University of Cordoba, Hospital Universitario Reina Sofia (HURS), Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), CIBERobn, and ceiA3, Córdoba, Spain, 3Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 4St Thomas Hospital, Lupus Research Unit, London, United Kingdom

    Background/Purpose:  The aim of this study was to evaluate whether alterations in the splicing-machinery could influence the development and activity of the disease and the…
  • Abstract Number: 2271 • 2016 ACR/ARHP Annual Meeting

    Mutation in Osteoprotegerin Gene: Early-Onset Osteoarthritis and Chondrocalcinosis in a US Family of Italian/German Ancestry

    Urooj Qazi1, Charlene J. Williams2, Mark L. Bernstein3, Aaron Charniak4, Amaryllis Ortiz2, Ann K. Rosenthal5, Lucien Cardinal1 and Alan T. Kaell1, 1Internal Medicine, SUNY Stony Brook Medicine-John T Mather Memorial Hospital, Port Jefferson, NY, 2Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ, 3Rheumatology, SUNY Stony Brook Medicine-John T Mather Memorial Hospital, Stony Brook, NY, 4SUNY Stony Brook Medicine-John T Mather Memorial Hospital, Port Jefferson, NY, 5Division of Rheumatology, Medical College of WI, Milwaukee, WI

    Background/Purpose: Chondrocalcinosis is characterized by calcium pyrophosphate dihydrate (CPPD) deposition in articular cartilage. It can occur as a rare autosomal dominant disorder with florid early-onset…
  • Abstract Number: 2415 • 2016 ACR/ARHP Annual Meeting

    Next Generation Sequencing Analysis of Familial Haemophagocytic Lymphohistiocytosis (HLH) Related Genes in Macrophage Activation Syndrome (MAS) and Secondary HLH (secHLH)

    Chiara Passarelli1, Manuela Pardeo2, Elisa Pisaneschi1, Antonio Novelli1, Fabrizio De Benedetti2 and Claudia Bracaglia2, 1Ospedale Pediatrico Bambino Gesù IRCCS, Unit of Medical Genetics, Laboratory of Cytogenetics and Molecular Genetics, Rome, Italy, 2Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy, Rome, Italy

    Background/Purpose: Macrophage activation syndrome (MAS) is a severe complication of rheumatic disease, particularly of systemic JIA (sJIA). It is currently classified among the secondary forms…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology